RUN vs SLRX · P/E 6.0, rev $2.04B vs $4.9M cap
Sunrun Inc (RUN) versus Salarius Pharmaceuticals Inc (SLRX) — a side-by-side from cached financials, not a winner call.
Sunrun Inc (RUN) is a solar company listed on NASDAQ.
Salarius Pharmaceuticals Inc (SLRX) is a biotechnology company listed on NASDAQ.
Latest reported RUN revenue for 2024-12-31 was $2.04B. Net income was -$4.36B. Revenue was down 9.8% from 2023-12-31 to 2024-12-31. RUN currently screens at market cap $3.05B and trailing P/E 6.0.
Latest reported SLRX revenue for 2023-03-31 was $0. Net income was -$5.3M. SLRX currently screens at market cap $4.9M.
RUN currently screens at market cap $3.05B and trailing P/E 6.0. SLRX currently screens at market cap $4.9M.
Not investment advice. Open the RUN and SLRX stock pages for the full models.
Not investment advice.